Results 251 to 260 of about 3,921,493 (313)

Author Correction: De novo antioxidant peptide design via machine learning and DFT studies. [PDF]

Sci Rep
Hesamzadeh P, Seif A, Mahmoudzadeh K, Ganjali Koli M, Mostafazadeh A, Nayeri K, Mirjafary Z, Saeidian H.   +7 more
europepmc   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Chemistry in Brazil: Building on a Legacy of Equitable Access. [PDF]

ACS Omega
Costa Reis M, Quina FH, Gupta K, Agarwal T, Imberti S, Andrade CH.   +5 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Correction: Aging and degradation behaviour of poly(lactic acid) composites in alcoholic and acidic food simulants. [PDF]

RSC Adv
Moldovan A, Sarosi I, Popescu V, Cuc S, Sarosi C, Zagrean-Tuza C, Silaghi-Dumitrescu R, Nemes O, Tiuc AE.   +8 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

The Seasons of a Career in Physical Chemistry: Olivia Harper Wilkins. [PDF]

ACS Phys Chem Au
Wilkins OH, Shea JE, Scholes GD, Solomon GC.   +3 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Correction: Conditional generation of free radicals by selective activation of alkoxyamines: towards more effective and less toxic targeting of brain tumors. [PDF]

Chem Sci
Piris P, Buric D, Yamasaki T, Huchedé P, Rossi M, Matteudi M, Montero MP, Rodallec A, Appay R, Roux C, Combes S, Pasquier E, Castets M, André N, Brémond P, Carré M.   +15 more
europepmc   +1 more source